BRAF G469S

CI-VAR-00001753Explore in graph →CIViC 3425

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
BRAF G469S	Dabrafenib + TrametinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID9515 Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469S increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC) PMID 28947956 · Noeparast et al., 2017 · Open in CIViC	civic
Multinodular and Vacuolated Neuronal Tumor1
BRAF G469S	(diagnostic)	Diagnostic	C	Supports Positive	2	submitted	EID12460 In an 11-year-old female presenting with seizures, a mixed MVNT with a ganglioglioma-like component located in the left temporal lobe revealed a BRAF p.G469S mutation (NM_004333.6:c.1405_1406delinsTC;…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.